I. Requirements for Prior Authorization of Multiple Sclerosis Agents

a. Prescriptions That Require Prior Authorization

Prescriptions for Multiple Sclerosis Agents which meet any of the following conditions must be prior authorized:

1. A prescription for a non-preferred Multiple Sclerosis Agent. See the Preferred Drug List (PDL) for the list of preferred Multiple Sclerosis Agents at www.providersynergies.com/services/documents/PAM_PDL.pdf

2. A prescription for Ampyra or Gilenya, regardless of the quantity prescribed.

3. A prescription for a preferred Multiple Sclerosis Agent with a prescribed quantity that exceeds the quantity limit. See Quantity Limits for the list of drugs with quantity limits at http://www.dpw.state.pa.us/provider/doingbusinesswithdpw/pharmacyservices/quantitylimitslist/index.htm

GRANDFATHER PROVISION – The Department will grandfather prescriptions for Multiple Sclerosis Agents for those recipients currently being prescribed a non-preferred Multiple Sclerosis Agent if the PROMISe Point-Of-Sale On-Line Claims Adjudication System verifies a record of payment by the Department for a prescription for a non-preferred Multiple Sclerosis Agent within the past 90 days from the date of service of the new claim. If there is a record of a prescription for a non-preferred Multiple Sclerosis Agent, a prescription or a refill for the same Multiple Sclerosis Agent will be automatically approved.

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a Multiple Sclerosis Agent, the determination of whether the requested prescription is medically necessary will take into account the following:

1. For a non-preferred Multiple Sclerosis Agent, whether the recipient:
   a. Has a diagnosis of a relapsing form of Multiple Sclerosis

   AND

   b. Has a documented history of therapeutic failure of a preferred Multiple Sclerosis Agent
OR

c. Has a documented history of contraindication or intolerance of the preferred Multiple Sclerosis Agents

OR

d. Has a current prescription (within the past 90 days) for the same non-preferred Multiple Sclerosis Agent

OR

2. For Ampyra, whether the recipient:

   a. Is 18 years of age or older

   AND

   b. Has a diagnosis of Multiple Sclerosis

   AND

   c. Is being prescribed Ampyra by a neurologist or physical medicine and rehabilitation specialist (PM and R)

   AND

   d. Has motor dysfunction on a continuous basis that impairs the ability to complete Instrumental Activities of Daily Living (IADL’s) or Activities of Daily Living (ADL’s) despite optimal treatment for Multiple Sclerosis

   AND

   e. Does not have a history of seizure

   AND

   f. Has a creatinine clearance of 50 ml/min or greater

FOR RENEWALS OF PRESCRIPTIONS FOR AMPYRA: Requests for prior authorization of renewals of prescriptions for Ampyra that were previously approved will take into account whether the recipient:

   a. Has a creatinine clearance of 50 ml/min or greater
b. Has a documented improvement in motor function

**OR**

3. For Gilenya, whether the recipient:

a. Has documented history of contraindication, intolerance or therapeutic failure of MS agents such as Copaxone, Interferon, etc.:

**AND**

b. Is 18 years of age or older

**AND**

c. Has a diagnosis of Relapsing Multiple Sclerosis

**AND**

d. Is being prescribed Gilenya by a neurologist

**AND**

e. Will be observed for 6 hours for signs and symptoms of bradycardia, following the first dose

**AND**

f. Has no evidence of active infection

**AND**

g. Is not receiving concomitant therapy with antineoplastic, immunosuppressive or immune modulating therapies

**AND**

h. Has documented positive antibodies for varicella zoster virus (VZV)

**AND**
i. Has not had a VZV vaccination in the previous one month

AND

j. Has a recent (previous 6 months) Complete Blood Count (CBC) with differential

AND

k. Has recent (previous 6 months) transaminase and bilirubin levels

AND

l. Has a recent (previous 3 months) EKG with no evidence of heart block or bradycardia

AND

m. Has a baseline (within previous 3 months) ophthalmologic exam of the macula

FOR RENEWALS OF PRESCRIPTIONS FOR GILENYA: Requests for prior authorization of renewals of prescriptions for Gilenya that were previously approved will take into account whether the recipient:

a. Has had improvement or stabilization of their Multiple Sclerosis as documented by the prescriber.

AND

b. Has no evidence of active infection

AND

c. Is not receiving concomitant therapy with antineoplastic, immunosuppressive or immune modulating therapies

AND

d. Had appropriate monitoring of their Complete Blood Count (CBC) with differential and LFTs

AND
e. Had a 3-4 month follow-up ophthalmologic exam of the macula following initiation of therapy  
   OR

f. For recipients with history of diabetes or uveitis, had a 3-4 month follow-up ophthalmologic exam of the macula following initiation of therapy and annually thereafter  
   OR

4. Does not meet the clinical review guidelines listed above, but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.

In addition, if a prescription for a Multiple Sclerosis Agent is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines that are set forth in the Quantity Limits Chapter.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above, to assess the medical necessity of the request. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.

D. Dose and Duration of Therapy

The Department will:

1. Limit initial approval of Ampyra to 3 months of therapy
2. Approve renewal of Ampyra for up to 12 months of therapy
3. Limit initial approval of Gilenya to 6 months of therapy
4. Approve a renewal of a prescription for Gilenya for up to 12 months of therapy

E. References:

1. Ampyra Package Insert, Acorda Therapeutics, Inc. January 2010
2. Gilenya Package Insert, Novartis Pharmaceuticals Co. September 2010